Novartis acquires commercial rights to Paratek antibiotic
This article was originally published in Scrip
Executive Summary
Novartis is to pay Paratek Pharmaceuticals' up to $485 million for the commercialisation rights to oral broad-spectrum antibiotic PTK 0796.